Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
StrokeMuscle Spasticity
Interventions
BEHAVIORAL

Optimal muscle activation therapy

The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.

BEHAVIORAL

Standard Therapy

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER